- Dec 18, 2018
They also claimed that "there is a risk of venous thromboembolism (problems due to the formation of blood clots in the veins) with the medicine"
But, according to their documentation, this was suffered by 5/1403 (0.35%) of recipients, 3 being morbidly obese and all having high estrogen, advancing age, and poor health. They said that because none were recorded in the control groups they can't rule out that the drug is dangerous, but the control groups were so much smaller that it's unlikely to see even a single case even if they occur at the same rate.
View attachment 20755